202 . 



Mr. Wyden. I think it is kind of interesting, you seem to recall 

 things from quite some time ago for Mr. Bliley. 



Mr. Sandefur. Right. 



Mr. Wyden. But you cannot recall a document that your com- 

 pany gave to this subcom.mittee while you were CEO? And I have 

 to tell you, I think that this is very interesting coincidence because, 

 after Project Wheat was completed and showed that there was a 

 very significant market for this kind of cigarette, the company de- 

 veloped the Barclay cigarette. 



And I would also say, subsequent to Project Wheat, we had a sit- 

 uation, as I think Congressman Synar got into, that you went for- 

 ward with this bioengineering situation so you could have plants 

 in effect with high nicotine and still meet this low tar situation. 



I think Project Wheat is something of a linchpin that ties to- 

 gether much of what we have been learning over the last few 

 months. High nicotine, low tar cigarettes are being developed for 

 the specific purpose of satisfying the nicotine cravings of smokers 

 who have got a high inner need for nicotine and you are just saying 

 all this kind of thing like the Barclay and the Y-1 genetic engineer- 

 ing was something of a coincidence that you know nothing about, 

 even though you submitted this document to the subcommittee. 

 And I guess that's a little hard for me to swallow but my time is 

 expired. 



Mr. Waxman. Mr. Wyden, I think we ought to give Mr. Sandefur 

 an opportunity to respond. 



Mr. Sandefur. Fd like to, Mr. Chairman. 



Mr. Wyden. He said, Mr. Chairman, he hasn't 



Mr. Waxman. You've made some serious charges and I think he 

 ought to respond. He's the chief executive officer of the company. 



Mr. Sandefur. Thank you, sir. 



Congressman Wyden, if you will look on the front page of this 

 document, you will see that it has been stamped Brown & 

 Williamson, February 26, 1976, research library. Now, there is ab- 

 solutely no way that a CEO of this company, or I would submit any 

 CEO of any company, knows what's in the research library of his 

 company. There is just no way. CEO's don't do that. 



Mr. Waxman. Well, Mr. Sandefur 



Mr. Sandefur. Excuse me. I'm sorry. We rely on our scientists 

 to tell us what they know and what they recommend and then we 

 make decisions based on that. I don't know, I wasn't at the com- 

 pany when Barclay was developed. I can tell you that there was 

 a great deal of controversy over the filter used on Barclay. And I 

 can also tell you that at the end of the day, the FTC decided on 

 what levels of tar and nicotine that we could say that Barclay de- 

 livered. So I can't speak to anj^hing other than that. 



Mr. Wyden. Mr. Sandefur, again, my time is up, but let me say 

 that this really requires an extraordinary set of coincidences that 

 I think are hard to believe. You have a study that shows that there 

 is a very large market out there for high nicotine, low tar ciga- 

 rettes because they would satisfy a craving of smokers with a very 

 significant inner need, a hunger for nicotine. 



We have the Barclay that comes after it in order to try to fulfill 

 that kind of need. We've got genetic engineering which again meets 



